Skip to main content
CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD. logo

CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD. — Investor Relations & Filings

Ticker · 000661 ISIN · CNE0000007J8 LEI · 300300X04OTKZG18WD66 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,288 across all filing types
Latest filing 2022-01-23 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000661

About CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD.

https://ccht.jl.cn

CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD. is a diversified enterprise primarily focused on the research, development, production, and distribution of biopharmaceuticals and healthcare products. The company operates through several key subsidiaries, most notably GeneScience Pharmaceuticals, which specializes in recombinant human growth hormones and pediatric endocrinology treatments. Its product portfolio includes biological drugs, vaccines, and traditional Chinese medicines, targeting therapeutic areas such as growth disorders, infectious diseases, and oncology. The group emphasizes technological innovation and maintains a significant presence in the domestic market while expanding its international footprint. In addition to its core life sciences business, the company maintains interests in real estate development and infrastructure management.

Recent filings

Filing Released Lang Actions
股票交易异常波动公告
Regulatory Filings Classification · 95% confidence The document is a stock trading abnormal fluctuation announcement by Changchun High-tech Industry (Group) Co., Ltd. It discusses the unusual stock price movement over three trading days, reasons for the fluctuation, company responses, and risk warnings. It does not contain financial statements or detailed financial data, nor is it a report or presentation. It is an official regulatory announcement related to stock price behavior and company disclosures. The document length is short (1700 characters), and it is not a report publication announcement or certification. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-01-23 Chinese
关于回购结果暨股份变动公告
Transaction in Own Shares Classification · 100% confidence The document is a detailed announcement about the completion of a share repurchase (buyback) program by the company 长春高新技术产业（集团）股份有限公司. It includes specifics on the number of shares repurchased, the price range, total amount spent, compliance with regulatory rules, and the intended use of the repurchased shares (for an equity incentive plan). It also confirms that the repurchase plan has been fully executed and provides information on the impact on shareholding structure. The document is not a financial report, earnings release, or management discussion, but a formal disclosure of the share repurchase results and related shareholding changes. This fits the definition of a Transaction in Own Shares (POS) filing, which reports on company buybacks or sales of its own shares.
2022-01-21 Chinese
关于部分董事、监事、高级管理人员增持公司股份的公告
Director's Dealing Classification · 100% confidence The document is an announcement regarding the purchase of company shares by certain directors, supervisors, and senior management personnel. It details the names, positions, dates, quantities, and prices of shares bought by these insiders. The content focuses on insider share transactions and compliance with relevant laws and regulations. There is no financial report, earnings data, or meeting information. This matches the definition of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives (insider trades). The document length is short and it is a direct announcement, not a report publication or certification. Therefore, the correct classification is DIRS with high confidence.
2022-01-21 Chinese
（2022-002）关于控股子公司重组人生长激素注射液新适应症补充申请获得批准的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from a company about the approval of a supplementary application for new indications of a pharmaceutical product by a regulatory authority (国家药品监督管理局 - National Medical Products Administration). It contains no financial data, no detailed financial statements, no management discussion, no voting results, no executive changes, no earnings information, and no report attachments. It is a regulatory announcement about product approval and market risk disclosure. The document length is short (741 characters), and it is clearly an announcement of regulatory approval rather than a financial or management report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-01-12 Chinese
关于股份回购进展情况的公告
Transaction in Own Shares Classification · 95% confidence The document is a public announcement regarding the progress of a share repurchase (buyback) plan by the company 长春高新技术产业（集团）股份有限公司. It details the number of shares repurchased, prices, compliance with regulations, and future intentions. The document is relatively short (1534 characters) and focuses on the status update of the share buyback program rather than presenting comprehensive financial data or a full report. This fits the definition of a Transaction in Own Shares (POS) filing, which covers reports of the company buying back or selling its own shares. There is no indication that this is a full financial report, an earnings release, or a regulatory filing unrelated to share repurchases. Therefore, the correct classification is POS with high confidence.
2022-01-04 Chinese
关于控股子公司重组人生长激素注射液新适应症补充申请获得批准的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Changchun High-tech Industry (Group) Co., Ltd. regarding the approval of a supplementary application for new indications of a recombinant human growth hormone injection by the National Medical Products Administration. It details the drug, the new approved indications, and includes a risk warning for investors. The document is short (824 characters) and serves as a regulatory announcement about product approval and related risks, not a financial report or detailed management discussion. It does not contain financial statements, earnings data, or management changes. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2021-12-31 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.